It has a lot to do with being an orphan drug. Companies will not innovate, develop drugs and run costly trials for small markets if they cannot charge a large premium for those small markets. That’s how orphan drug pricing works. So yes, we could charge a fair bit higher for PPS for MPS versus PPS for OA and justifiably so.
Just IMO and DYOR.
Ann: Paradigm AGM Presentation, page-37
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.5¢ | $89.62K | 294.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20607 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16773 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |